<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684058</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436G2201</org_study_id>
    <secondary_id>2015-004015-20</secondary_id>
    <nct_id>NCT02684058</nct_id>
  </id_info>
  <brief_title>Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG</brief_title>
  <official_title>Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the activity of dabrafenib in combination with
      trametinib in children and adolescent patients with BRAF V600 mutation positive low grade
      glioma or relapsed or refractory high grade glioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Anticipated">September 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HGG cohort: Overall response rate (ORR)</measure>
    <time_frame>Within the first 32 weeks of treatment</time_frame>
    <description>HGG cohort: ORR as determined by investigator assessment based on Magnetic resonance imaging MRI) or CT (CAT) scans using Response Assessment in Neuro-Oncology Criteria (RANO) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LGG cohort: Overall response rate (ORR)</measure>
    <time_frame>Within the first 32 weeks of treatment</time_frame>
    <description>LGG cohort: ORR as determined by blinded independent review based on MRI or CT scans using RANO criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HGG cohort: Overall response rate (ORR)</measure>
    <time_frame>Within the first 32 weeks of treatment</time_frame>
    <description>HGG cohort ORR as determined by central independent review based on Magnetic resonance imaging (MRI) or CT (CAT)scans using Response Assessment in Neuro-Oncology (RANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Duration of response (DOR)</measure>
    <time_frame>Within the first year of treatment</time_frame>
    <description>HGG and LGG cohorts: DOR as assessed separately by investigator and central review based on MRI or CT scans using RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Time to response (TTR)</measure>
    <time_frame>Within the first year of treatment</time_frame>
    <description>HGG and LGG cohorts: TTR as assessed separately by investigator and central review based on MRI or CT scans using RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Overall survival (OS)</measure>
    <time_frame>2 years from last patient dosed</time_frame>
    <description>HGG and LGG cohorts: OS as defined as the time from first dose to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Progression free survival (PFS)</measure>
    <time_frame>Within 4 months of treatment</time_frame>
    <description>HGG and LGG cohorts: PFS as assessed separately by investigator and central review based on MRI or CT scans using RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients on DRB+TMT: Area under the curve (AUClast)</measure>
    <time_frame>Within the first month of treatment</time_frame>
    <description>Patients on DRB+TMT: Assessed from time zero to the last measurable sampling time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients on DRB+TMT: Area under the curve (AUCtau)</measure>
    <time_frame>Within the first month of treatment</time_frame>
    <description>Patients on DRB+TMT: Calculated to the end of a dosing interval at steady state (12 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients on DRB+TMT: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Within the first month of treatment</time_frame>
    <description>Patients on DRB+TMT: The maximum (peak) observed plasma drug concentration after a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients on DRB+TMT: Time to reach maximum concentration (Tmax)</measure>
    <time_frame>Within the first month of treatment</time_frame>
    <description>Patients on DRB+TMT: The time to reach maximum (peak) concentration of study drug after a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients on DRB+TMT: Elimination half-life (T1/2)</measure>
    <time_frame>Within the first month of treatment</time_frame>
    <description>Patients on DRB+TMT: The elimination half-life associated with the terminal slope of a semi-log concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients on DRB+TMT: Predose plasma concentration (Ctrough)</measure>
    <time_frame>Within the first month of treatment</time_frame>
    <description>Patients on DRB+TMT: Measured concentration at the end of a dosing interval at steady state, taken directly before next study drug administration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Adverse events</measure>
    <time_frame>From first dose to end of treatment (EOT)</time_frame>
    <description>HGG cohort: Incidence of AEs and SAEs reported during treatment with dabrafenib and trametinib in this population. LGG cohort: Incidence of AEs and SAEs reported during treatment with dabrafenib and trametinib as compared to chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Vital signs</measure>
    <time_frame>First dose to end of treatment</time_frame>
    <description>HGG: Assess the safety of dabrafenib and trametinib in this population through monitoring changes in vital signs. LGG: Assess the safety of dabrafenib and trametinib in this population as compared to chemotherapy through monitoring changes in vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Abnormal lab values</measure>
    <time_frame>First dose to end of treatment</time_frame>
    <description>HGG: Assess the safety of dabrafenib and trametinib in this population through hematology, chemistry and urinalysis tests. LGG: Assess the safety of dabrafenib and trametinib in this population as compared to chemotherapy through hematology, chemistry and urinalysis tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: Changes in Electrocardiogram (ECG)</measure>
    <time_frame>First dose to end of treatment</time_frame>
    <description>HGG: Assess the safety of dabrafenib and trametinib in this population through changes in ECG values. LGG: Assess the safety of dabrafenib and trametinib as compared to chemotherapy in this population through changes in ECG values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohorts: ECHO</measure>
    <time_frame>First dose to end of treatment</time_frame>
    <description>HGG: Assess the safety of dabrafenib and trametinib in this patient population through changes in ECHO results. LGG: Assess the safety of dabrafenib and trametinib in this patient population as compared to chemotherapy through changes in ECHO results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LGG cohort: Overall response rate (ORR)</measure>
    <time_frame>Within the first 32 weeks of treatment</time_frame>
    <description>LGG cohort: ORR as determined by investigator assessment based on MRI or CT scans using RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG cohort: Palatability of pediatric formulations</measure>
    <time_frame>Within the first 5 weeks of treatment</time_frame>
    <description>HGG and LGG cohort: Palatability questionnaire data for DRB suspension and TMT solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LGG cohort: PROMIS Parent Proxy scale</measure>
    <time_frame>Within the first 32 weeks of treatment</time_frame>
    <description>LGG cohort only: PROMIS parent proxy scale to estimate differences between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HGG and LGG Cohorts: Clinical benefit rate (CBR)</measure>
    <time_frame>Within the first 24 weeks of treatment</time_frame>
    <description>HGG and LGG cohorts: CBR as assessed separately by investigator and central review of MRI and CT scans per RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LGG cohort: 2 year Overall survival (OS)</measure>
    <time_frame>2 years from first dose</time_frame>
    <description>LGG cohort: OS as defined as the time from the first dose to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Diffuse Astrocytoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Astrocytoma</condition>
  <condition>Oligodendroglioma, Childhood</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Pilocytic Astrocytoma</condition>
  <condition>Giant Cell Astrocytoma</condition>
  <condition>Pleomorphic Xanthoastrocytoma</condition>
  <condition>Anaplastic Pleomorphic Xanthoastrocytoma</condition>
  <condition>Angiocentric Glioma</condition>
  <condition>Chordoid Glioma of Third Ventricle</condition>
  <condition>Gangliocytoma</condition>
  <condition>Ganglioglioma</condition>
  <condition>Anaplastic Ganglioglioma</condition>
  <condition>Dysplastic Gangliocytoma of Cerebrellum</condition>
  <condition>Desmoplastic Infantile Astrocytoma and Ganglioglioma</condition>
  <condition>Papillary Glioneuronal Tumor</condition>
  <condition>Rosette-forming Glioneurona Tumor</condition>
  <condition>Central Neurocytoma</condition>
  <condition>Extraventricular Neurocytoma</condition>
  <condition>Cerebellar Iponeurocytoma</condition>
  <arm_group>
    <arm_group_label>HGG cohort: Dabrafenib and trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGG cohort: All patients in the HGG cohort will receive DRB+TMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGG cohort: Carboplatin with vincristine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGG cohort: Dabrafenib and trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>dabrafenib oral, twice daily.</description>
    <arm_group_label>HGG cohort: Dabrafenib and trametinib</arm_group_label>
    <arm_group_label>LGG cohort: Dabrafenib and trametinib</arm_group_label>
    <other_name>DRB436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>trametinib oral, once daily.</description>
    <arm_group_label>HGG cohort: Dabrafenib and trametinib</arm_group_label>
    <arm_group_label>LGG cohort: Dabrafenib and trametinib</arm_group_label>
    <other_name>TMT212</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin with vincristine</intervention_name>
    <description>Chemotherapy of carboplatin with vincristine - LGG only</description>
    <arm_group_label>LGG cohort: Carboplatin with vincristine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of BRAF V600 mutant High Grade glioma that has relapsed, progressed or
             failed to respond to frontline therapy

          -  Diagnosis of BRAF V600 mutant Low Grade glioma whose tumor is unresectable and who
             require treatment

          -  Confirmed measurable disease

        Exclusion Criteria:

          -  Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK
             inhibitor

          -  Cancer treatment within the past 3 weeks

          -  Stem cell transplant within the past 3 months

          -  History of heart disease

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seda Carlton</last_name>
      <email>Seda.carlton@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Lindsey Hoffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens National Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Malik</last_name>
      <phone>202-884-2120</phone>
      <email>samalik@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Roger Packer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University IDS Pharmacy John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Rice</last_name>
      <email>willipa@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianne Greenspan</last_name>
      <phone>617-632-3352</phone>
      <email>Lianne_Greenspan@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Mark W. Kieran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Zacharko</last_name>
      <email>pzacharko@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Ginn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center PC-2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Hsuan Chen</last_name>
      <phone>646-888-5722</phone>
      <email>chenm2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Gilheeney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center UTSW/Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Patterson</last_name>
      <email>alison.patterson@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Theodore Laetsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant glioma</keyword>
  <keyword>BRAF mutant positive</keyword>
  <keyword>High grade glioma</keyword>
  <keyword>Low grade glioma</keyword>
  <keyword>Dabrafenib</keyword>
  <keyword>Trametinib</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Brain neoplasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Ganglioglioma</mesh_term>
    <mesh_term>Neurocytoma</mesh_term>
    <mesh_term>Ganglioneuroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

